🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are escalating globally, with estimates suggesting over 82 million infections each year. Particularly high rates are observed in the African continent and nations within the WHO's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited treatment choices at this time.”

Medical experts are increasingly worried about the surge in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance found that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Secure Approval

One new antibiotic, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Scientists anticipate that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, was also approved in close succession. This drug, which is additionally indicated for urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm Innoviva to bring it to fruition.

“This approval represents a huge turning point in the treatment of superbug gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Outcomes and Global Access

Based on data released by a major medical journal, the new drug cured over nine in ten of cases of the STI. This places it at an similar efficacy with the typical regimen, which involves an injection and a pill. The trial included nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the ability to make available and distribute the drug in many low-income and middle-income countries.

Clinicians on the front lines have shared positive views. Having a single-dose, oral treatment of this kind is described as a "game-changer" for managing the epidemic. This is deemed vital to lessen the impact of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea worldwide.